Article
CAF-released galectin 1 mediates non-cell-autonomous resistance to ceritinib in NSCLC.
2023-07-31
Abstract excerpt
<title>Abstract</title> <p>Background Despite the advent of second and third-generation compounds targeting ALK in ALK-addicted Non-Small Cell Lung Cancer (NSCLC), this tumor remains largely incurable due to drug resistance. A variety of cell-autonomous mechanisms have been shown to mediate acquired resistance to ALK tyrosine kinase inhibitors (TKIs); however, if and how tumor stroma can drive resistance to ALK...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a0c1c202-5c0c-561f-bfc8-dfe67c38de3a
- DOI
- 10.21203/rs.3.rs-3192164/v1
